I understand that the data for the first 3 patients will be released by the end of the month.
However I don’t believe CHM have provided specific timing on the release of data for the second and third cohorts, other than general remarks about “when the data becomes available”. I do recall Rebecca saying in passing during an investor update that she would review the cadence for reporting on the later cohorts (implying that she wouldn’t wait until all three patients were dosed and assessed).
this accelerated disclosure of CDH17 results is not typical of biotech companies. Usually there is a very long lead time before any results are released. Look at IMU which has dozens of employees and burning thru $20m per qtr - it has released precious little data about its trials (other than Azer Cel) over the last few years.
CHM Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)